News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CLX Investment Company (CLXN) Issues March 2008 Newsletter Reviewing Preparations for Clinical Trials on Zonda, Inc.'s Rapid Point of Care Test for Chlamydia Including Planned Validation Study



3/25/2008 9:37:43 AM

MURRIETA, CA--(Marketwire - March 25, 2008) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today released the March 2008 issue of its investor newsletter, which highlights the recent announcements regarding the company's preparations for planned clinical trials on Zonda's rapid point of care test for chlamydia. Clinical trials are being undertaken as part of the company's efforts to achieve FDA clearance for the chlamydia test and to begin distribution in the United States.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES